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Objective: Deficits in motor inhibition may contribute to impulsivity and irritability in
children with bipolar disorder (BPD). Therefore, studies of the neural circuitry engaged during
failed motor inhibition in pediatric BPD may contribute to our understanding of the
pathophysiology of the illness. We tested the hypothesis that children with BPD and controls
would differ in ventral prefrontal cortex (vPFC), striatal, and anterior cingulate activation
during unsuccessful motor inhibition. We also compared activation in medicated vs.
unmedicated children with BPD, and in children with BPD and ADHD (BPD+ADHD) vs.
those with BPD but without ADHD (BPD-ADHD).

Method: Event-related fMRI study comparing neural activation in children with BPD and
controls while they performed a motor inhibition task. The sample included 26 children with
BPD (13 unmedicated, 15 with ADHD) and 17 age, gender, and IQ matched controls.

Results: On failed inhibitory trials, controls showed greater bilateral striatal and right vPFC
activation than did patients. While our findings were somewhat more prominent in
unmedicated than medicated, patients, and in BPD+ADHD than BPD-ADHD, the findings did
not differ significantly (?) among these subgroups of children with BPD.

Conclusions: Compared to controls, children with BPD may have deficits in their ability to
engage striatal structures and right vPFC during unsuccessful inhibition. (this reads
confusingly to me—they’re deficient in their capacity to engage structures when they’re
behaviorally unsuccessful? Perhaps reword?) Further research is needed to determine whether
these deficits play a role in the emotional and behavioral dysregulation characteristic of BPD.
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Introduction
Deficits in motor inhibition might produce symptoms of impulsivity and affective
aggression in pediatric BPD (1, 2) while also contributing to diagnostic confusion between
attention deficit hyperactivity disorder (ADHD) and BPD (3). The neural circuitry engaged
during unsuccessful motor inhibition in pediatric bipolar disorder (BPD) is therefore of
interest. Research on the pathophysiology of these shared motor symptoms could identify
common and distinct neural mechanisms between ADHD and BPD. Finally, motor inhibition
is mediated by the ventral prefrontal cortex (vPFC), striatum, and anterior cingulate, areas
implicated in the pathophysiology of BPD (4-12).
The current study selected regions of interest (ROIs) based on studies implicating
common brain regions in BPD and motor inhibition. fMRI studies in adult BPD found patientcontrol differences in vPFC activation during various tasks (13, 14) (15, 16). One study in
children with both BPD and a family history of the illness found that, compared to controls,
patients had increased vPFC activation while viewing emotional pictures or performing a
spatial working memory task(17). In the same study, children with BPD had greater anterior
cingulate activation than controls during the spatial working memory task, consistent with
fMRI(18, 19) studies in bipolar adults. With regard to the striatum, four studies in BPD (two
of adults, two of youth) reported increased activation in patients vs. controls.
We studied vPFC, striatal, and cingulate activation in children with BPD who
performed an event-related version of the stop signal task, a motor inhibition paradigm used to
study ADHD (20). Because the failure to appropriately inhibit a motor response is an
important symptom in pediatric BPD, we were particularly interested in circuitry engaged
during unsuccessful motor inhibition. The stop signal paradigm includes two features that
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facilitate the study of such circuitry. First, the paradigm adjusts difficulty based on subject
performance, so that all subjects fail to inhibit on approximately 50% of inhibitory trials. This
ensures a relatively large number of unsuccessful inhibitory (“stop incorrect”) trials to contrast
with both successful inhibitory (“stop correct”) trials and go trials. Second, all trials begin
with a go signal, followed in approximately 25% of trials, by a stop signal. Thus, the contrast
of “stop incorrect” vs. “go” trials controls for the presence of both a motor response and a go
signal, thus isolating circuitry engaged during failed motor inhibition. In addition, the “stop
correct” vs. “stop incorrect” contrast examines the circuitry engaged during successful
inhibition. This contrast controls for stimulus properties (i.e. the presence of both go and stop
signals), but not for the presence or absence of a motor response.
In research in this area, two potential confounds deserve particular attention:
medication and comorbid ADHD. We recruited enough children with BPD to compare neural
activation in medicated vs. unmedicated patients, and in those with vs. without ADHD. Such
comparisons are rare in the literature. One fMRI study of adult bipolar patients compares
unmedicated to medicated patients (REF Caliguiri). All other published fMRI studies in BPD
include predominantly medicated subjects (NEED REFS). Similarly, while studies find
comorbid ADHD in at least 60% of children with BPD (REF), previous fMRI studies have not
compared activation in bipolar children with and without comorbid ADHD.
We used rapid event-related fMRI and the stop signal task to study motor inhibition in
children with BPD. Given the clinical importance of failed motor inhibition in pediatric BPD,
we focused on circuitry engaged during unsuccessful inhibition. Because the vPFC, anterior
cingulate, and striatum have been implicated in both motor inhibition and BPD, we
hypothesized that patients and controls would differ in activation in these regions. In addition,
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we compared activation in medicated patients vs. unmedicated patients, and in bipolar patients
with ADHD (BPD+ADHD) vs. those without ADHD (BPD-ADHD).

Methods
Subjects
The patient group consisted of XX youth recruited via advertisements to patient
advocacy groups. All patients met DSM-IV diagnostic criteria for BPD and exhibited the
narrow phenotype of BPD, in that each had a history of at least one hypomanic or manic
episode meeting full duration criteria and including expansive, elevated mood(3). Patients
were excluded if they had severe Pervasive Developmental Disorder, substance use within the
past 3 months, or IQ<70. A best-estimate diagnostic approach was used, as described
elsewhere (give ref), integrating data from the Schedule for Affective Disorders and
Schizophrenia (K-SADS-PL(21); parent and child were interviewed separately by clinicians,
master’s level or above, with kappa > 0.9), treating physicians, and medical records. Comorbid
diagnoses were assigned only if the patient met criteria for the comorbid diagnosis while
euthymic. Thus, the diagnosis of comorbid ADHD could not be due to the overlap between
symptoms of ADHD and those of mania or hypomania.
Of the XX patients scanned, data from 26 were usable. A priori exclusion criteria
included inadequate task performance (i.e., < 65% correct on go trials) or excessive movement
(> 2.5 mm in any plane). Data were not usable for YY patients, and the clinical data provided
below includes only the 26 patients with usable scanning data.
Comorbid disorders were common (Table 1). Fifteen patients (58%) had a comorbid
diagnosis of ADHD. Clinicians completed mood ratings (Young Mania Rating Scale
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(YMRS)(22) and Children’s Depression Rating Scale (CDRS)(23)) within 24 hours of
scanning (Table 1). Five patients were hypomanic (YMRS score>12 but<=20) and the
remaining 21 were euthymic. Thirteen patients (50%) were medicated (for medication types,
see Table 1).
Controls comprised 26 youth with no K-SADS-PL(24) diagnosis, no DSM-IV
diagnoses in first-degree relatives (family history was ascertained by parent interview), no use
of psychoactive substances, and IQ>70. Of the 26 scanned controls, data from 17 were usable.
Groups did not differ significantly on age, gender, or IQ(25) (Table 1). The study was
approved by the NIMH IRB; participants and a parent provided written informed
consent/assent.

Behavioral Task
The task was based on previously published work (26, 27). On all trials, a white
fixation cross appeared for 500 ms; it was replaced by an “X” or “O” “go-signal” for 1000 ms
(Fig.1). Using a button-box, subjects pressed “1” for “X” and “2” for “O”. Subjects were told
to respond within 1000 ms, unless the background changed to red, which occurred on 25% of
the trials (i.e. stop trials). In these instances, they were instructed not to press either button.
On the first stop trial, the stop signal appeared 250 ms after the go-signal. Subsequent
stop-signal timing was based on subject performance. If the subject successfully inhibited, the
next stop signal appeared 50 ms later, making inhibition more difficult; if the subject failed to
inhibit, the signal appeared 50 ms earlier, making inhibition easier. Trials were separated by
750 ms.
Prior to scanning, subjects were trained to achieve a mean reaction time (RT) less than
1000 msec on “go” trials and successful inhibition on 40-60% of stop trials. Subjects received
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feedback after each block during scanning; they were told to decrease their reaction time if the
mean exceeded 1000 ms.

Scanning acquisition
Scanning occurred in a GE Signa 3Tesla magnet at NIMH. Head movement was
restricted with padding; images were presented via Avotec Silent Vision Glasses (Stuart, FL).
Gradient echo planar images (EPI) were acquired after sagittal localization and manual
shimming. EPI images used 23 contiguous 5mm axial slices, parallel to the AC-PC line, and
EPI single-shot gradient echo T2* weighting (matrix 64x64; TR =2000 ms; TE =40 ms; Field
of View =240 mm; voxels 3.75x3.75x5 mm).
Subjects completed four runs, each with 32 go, 16 stop, and 16 blank fixation trials
distributed randomly throughout each block. Blank fixation trials were included, based on the
“rapid-event-related” paradigm of Holmes and Friston (REF), and Zarahn (REF), to allow
deconvolution of unique events occurring close in time. These trials provide an implicit
statistical baseline (REF Zarahn).
A high resolution T1 weighted anatomical image was acquired for spatial
normalization. A standardized magnetization prepared gradient echo sequence was used (180
1 mm sagittal slices; FOV = 256; NEX = 1; TR = 11.4 ms; TE = 4.4 ms, matrix = 256x256; TI
= 300 ms; bandwidth = 130 Hz/pixel, 33kHz/256 pixels).
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Data Analysis
Behavioral data
The following were recorded during scanning: RT and accuracy on go trials (GoRT),
accuracy on stop trials, and inhibit delay (i.e. interval between the onsets of the go and stop
signals). The stop signal reaction time (SSRT), or speed of inhibition, was calculated. When a
subject inhibits successfully on 50% of stop trials, the SSRT is the mean GoRT minus the
mean inhibit delay (27, 28). Since subjects’ accuracy on stop trials may deviate from 50%, an
interpolation algorithm was used to calculate SSRT: the mean stop signal delay was subtracted
th

from the GoRT at the x percentile, where x is the subject’s % accuracy on stop trials.

Imaging data
Primary analyses
Analyses were conducted with SPM99b. Preprocessing included slice time correction,
motion correction, and spatial normalization. At the subject level, event-related response
amplitudes were estimated using the General Linear Model (GLM). Event types included
unsuccessful stop (“stop-incorrect”), “correct-go” (“go”; N.B. hereinafter, “go” refers only to
correct go trials), and successful-stop (“stop-correct”) trials. A rectangular pulse (2250 msec,
the length of each event) was used to model each event, convolved with the hemodynamic
response function provided by SPM. A high pass filter of .024 Hz was applied.
Contrast images were created for each subject using pairwise comparisons of eventrelated response amplitudes. The primary analysis was activation on stop-incorrect vs. go
trials, in BPD vs. controls. We also compared activation on stop-correct vs. stop-incorrect
trials, in BPD vs. controls. For both contrasts, subsequent analyses compared medicated
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patients to controls, unmedicated patients to controls, and unmedicated to medicated patients.
In addition we compared BPD+ADHD to controls, BPD-ADHD to controls, and BPD+ADHD
to BPD–ADHD on both contrasts.
Prior to group analysis, each contrast image was proportionally scaled. These
normalized contrast images were smoothed using an isotropic Gaussian kernel (FWHM = 11.4
mm). A group level random effects model was employed to provide population levelinference.
A small volume corrected, ROI analysis was used: the ROIs were bilateral vPFC,
striatum (accumbens, caudate, putamen), and anterior cingulate. Significance was set at p<.05.
ROI templates were defined on the canonical single subject’s structural MRI images supplied
by SPM99. Templates were defined using MedEx software, drawn by hand in the coronal
plane, and applied to all normalized brains at the group level. Coordinates are in Montreal
Neurological Institute (MNI) space. The cingulate, putamen, and caudate were ascertained
from standard anatomical criteria.(29-32). The accumbens was identified at the inferior
junction between the head of the caudate and putamen. It was delimited superiorly by a line
connecting the inferior corner of the lateral ventricle and the inferior point of the internal
capsule abutting the accumbens, and laterally by a vertical line passing from the latter
point(33). The vPFC boundaries were defined as the last slice with the anterior horizontal
ramus, the last slice containing the olfactory sulcus, anterior horizontal ramus, and the
olfactory sulcus (Monk, 2003; McClure Bio Psych gender paper, 2004).

Results
Behavioral Data
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There were no between-group differences in mean inhibit delay, go RT, stop accuracy,
or SSRT, but patients had significantly lower go accuracy than controls (Table 2). In the fMRI
analysis, to control for between-group differences in stop and go accuracy, only correct go
trials were used; stop-correct and stop-incorrect trials were analyzed separately. There were no
significant behavioral differences between unmedicated and medicated patients, or between
BPD+ADHD vs. BPD-ADHD.

Imaging data
Stop incorrect vs. go
All bipolar patients vs. controls: Bipolar patients did not show increased activation
relative to controls in any ROI. However, controls had greater activation than patients in
caudate, putamen, accumbens, and vPFC (Table 3).
Effect of medication: There were no significant differences between unmedicated and
medicated patients in any ROI. The comparisons of controls vs. medicated patients, and of
controls vs. unmedicated patients, yielded similar results. That is, controls had greater
activation than unmedicated patients in accumbens, caudate, and putamen, with a trend toward
increased activation in vPFC (Table 3). Similarly, controls had greater activation than
medicated patients in left accumbens, left caudate, and right vPFC, with a trend toward greater
activation in right accumbens (Table 3).
Effect of comorbid ADHD: There were no significant differences between BPD+ADHD
and BPD-ADHD in any ROI. Controls had greater activation than did BPD+ADHD in striatum
(bilateral accumbens, caudate, and putamen), as well as bilateral anterior cingulate and vPFC
(Table 3). The differences between controls and BPD-ADHD were limited to the striatum,
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with controls having greater activation in bilateral accumbens and left caudate, with a trend
toward greater activation in left putamen (Table 3).

Stop correct vs. stop incorrect
All bipolar patients vs. controls: With all bipolar patients included in the analysis,
patients had increased activation compared to controls in the right vPFC (Table 3). Patients
and controls did not differ on any other ROI.
Effect of medication: ,There were no significant differences between medicated patients
and controls in any ROI. However, unmedicated patients had significantly greater activation
than controls in bilateral accumbens, caudate, and putamen, in right OFC, and in right anterior
cingulate (Table 4). Similarly, unmedicated patients had significantly greater activation than
did medicated patients in bilateral accumbens, left putamen, and right caudate (Table 4).
Effect of comorbid ADHD: , There were no significant differences between BPD–
ADHD and controls in any ROI. However, BPD+ADHD had greater activation than controls
in right accumbens, right putamen, and right vPFC (Table 4). BPD+ADHD also had greater
activation than BPD-ADHD in bilateral accumbens, putamen, and vPFC, and left caudate
(Table 4).

Across-condition comparison at peak voxels
These results indicate greater striatal and right vPFC activation in controls than patients
in the stop incorrect vs. go contrast, and greater striatal and right vPFC activation in patients
than controls in the stop correct vs. stop incorrect contrast. These findings could both be due to
increased striatal and vPFC activation in controls, compared to patients, on incorrect stop trials.
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To explore this possibility, for the right vPFC and each striatal ROI, we identified the voxel
showing the greatest between-group difference in the stop incorrect vs. go contrast. For that
voxel, we plotted the mean beta on the stop correct vs. fixation, stop incorrect vs. fixation, and
go vs. fixation contrasts. Blank fixation trials were used so that the responses to the other
conditions could be estimated efficiently (Friston, Zarahn, Josephs et al, NeuroImage 10,
607—619, 1999). This yielded a series of histograms, one for each striatal area and one for
right vPFC. Each histogram showed a similar pattern: i.e., controls showed significantly
greater activation than patients on stop incorrect trials (see Fig. X).

Discussion
Given the importance of failed inhibition in the clinical presentation of pediatric BPD,
we used rapid event-related fMRI to study the neural circuitry engaged during unsuccessful
inhibitory trials. On such trials, controls showed greater bilateral striatal and right ventral
prefrontal activation than did patients. While our findings were somewhat more prominent in
unmedicated, compared to medicated, patients, and in BPD+ADHD, compared to BPDADHD, the findings did not differ significantly (?) among these subgroups of children with
BPD.
Whereas SSRT did not differ between groups in these small samples, data from a larger
sample indicate a trend suggesting that bipolar patients may be slower than controls to inhibit
prepotent responses (34). Moreover, data from related tasks indicate that children with BPD
have deficits in motor regulation (34). Neuroimaging and basic research implicate the striatum
in the learning and execution of motor programs (35). Recent research in adults indicates
striatal engagement with increasing neurocognitive load (36), and animal research suggests that
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striatal dopaminergic neurons produce error signals(37). (this paragraph doesn’t flow—
perhaps rewrite the preceding 3 sentences to soften the jump from deficient motor regulation to
striatal function) Data presented here and elsewhere(34) suggest that motor inhibition deficits
in pediatric BPD may reflect a failure to engage the striatum appropriately during failed
inhibition.
Our finding contrasts with four studies showing increased, rather than decreased,
striatal activation in patients with BPD vs. controls(38-41). Various factors could account for
such inconsistencies. None of the studies finding striatal hyper-activation used a motor
inhibition paradigm, although one(42) did employ an interference task. Moreover, we
examined neural activation on a trial-by-trial basis in relation to subject behavior unlike prior
studies in which behavioral data were not obtained(43, 44), block designs were used(45), or
ceiling-effects occurred (46). While the data presented here indicate decreased striatal
activation in patients vs. controls during failed inhibition, we have observed increased striatal
activation in patients vs. controls in a different psychological context (unpub data); a similar
phenomenon has been reported with regard to dorsolateral prefrontal function in patients with
schizophrenia (Callicott, AJP 2003). Thus, striatal dysfunction in BPD may manifest
differently across different situations.
These results may elucidate how striatal dysfunction contributes to disinhibition and
other affective and behavioral impairments in pediatric BPD. Patients with BPD have motor
abnormalities in both depressed and manic states i.e., hyperactivity in mania and hypo- or
hyperactivity in depression. Also, impulsivity is an important clinical feature of BPD, across
mood states and between episodes. In adults with BPD, impulsivity is frequently associated
with risky behavior such as substance abuse, present in 60% of adults with BPD (47). In
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children with BPD, impulsivity is associated with irritability, and both are impairing across
mood states (48). Data in control children suggest that irritability and decreased motor
inhibition may be related mechanistically: in controls, impaired motor inhibition (i.e., increased
SSRT) is associated with increased intensity of experienced anger(49). Speculatively, we
suggest that the impulsivity seen in patients with BPD across the developmental spectrum is
associated with failure to engage the striatum in situations requiring motor inhibition. If so,
interventions that facilitate striatal engagement in such contexts might provide avenues to
decrease impulsivity in BPD.
We found between-group differences in the right vPFC that, although less robust and
consistent than those in the striatum, followed a similar pattern, in which controls showed
greater vPFC activation than patients on failed inhibitory trials. The congruence of our vPFC
and striatal findings is consistent with nonhuman primate research indicating significant
structural and functional connections between the two regions (REF).
With one exception (Caligiuri), fMRI studies of neither children nor adults with BPD
have examined the impact of either medication or comorbid illnesses on neural activation.
Using a simple motor task, Caligiuri et al reported increased cortical and subcortical activation
in bipolar adults that was normalized by medication. We also found that medication dampened
patient-control differences, suggesting that studies of medicated patients might be prone to
Type II, rather than Type I, errors. With regard to comorbid ADHD, we found that bipolar
children with or without ADHD differed from controls in striatal activation during failed
inhibition (i.e., on the stop incorrect vs. go contrast). However, on the stop correct vs. stop
incorrect contrast, BPD+ADHD, but not BPD-ADHD, differed from controls, and
BPD+ADHD differed from BPD-ADHD in activation on several ROIs. Thus, the impact of
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comorbidity on fMRI results in pediatric BPD can be complex, varying from contrast to
contrast and, possibly, with the behavioral paradigm. Finally, it is unclear whether the
pathophysiology of ADHD symptoms is the same in children with BPD and children with
ADHD only or, alternatively, whether ADHD in children with BPD is a phenocopy of the more
common forms of ADHD(50). Indeed, whereas we found increased right vPFC activation in
BPD+ADHD vs. controls on the stop correct vs. stop incorrect contrast, a study in ADHD
children found that patients, compared to controls, had significantly reduced activation in the
right inferior frontal PFC during successful inhibition (Rubia, AJP, 2005). CHECK THIS
Follow-up research should compare fMRI data from children with ADHD only to children with
BPD. Also, further study is needed to ascertain the possible impact of mood state on our
results. Since 18 of 22 patients were euthymic, the deficits we identified may be trait-related,
but more definitive work is needed.
In sum, our data indicate that, compared to controls, children with BPD may have
deficits in their ability to engage striatal structures and right vPFC during unsuccessful
inihibition. These results may give clues to the pathophysiology of disinhibition and
impulsivity in BPD.
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Table 1. Demographic and clinical characteristics
Characteristic

Controls (N=17)

Bipolar (N=26)

Gender: % male (N)

53 (9)

Age (years; mean + SD)

14.6+1.8

13.6+2.6

WASI FSIQ (mean + SD)

109.9 + 12.3 (N=15)

106.7+13.0 (N=22)

46 (12)

Bipolar I: % (N)

--

91.7 (22) (two missing)

Bipolar II: % (N)

--

8.3 (2)

Young Mania Rating Score
(mean + SD)
Children’s Depression Rating Score
(mean + SD)
# Comorbid diagnoses (mean + SD)

--

7.3 + 5.5

--

24.3 + 6.1

--

1.4+1.0 (two missing)

Comorbid ADHD1: % (N)

--

57.7 (15)

Comorbid anxiety disorder: % (N)

--

54.2 (13) (two missing)

Comorbid ODD/CD2: % (N)

--

37.5 (9) (two missing)

Unmedicated: % (N)

--

50% (13)

# of Medications (mean + SD)3

--

3.2 + 1.1

Atypical Antipsychotic: % (N)

--

84.6 (11)

Lithium: % (N)

--

46.2 (6)

Anti-Epileptic Drug (AED)4: % (N)

--

84.6 (11)

Antidepressant: % (N)

--

30.8 (4)

Stimulant: % (N)

--

30.8 (4)

Other: % (N)

--

15.4 (2)

1= Attention deficit hyperactivity disorder; 2= Oppositional defiant disorder or conduct
disorder; 3=Only children on medication are included in this analysis; 4=includes
oxcarbamazepine, topiramate, lamotrigine, carbamazepine, sodium valproate, clonazepam
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Table 2. Performance on the stop signal task during scanning

Variable (mean + SD)

Controls (N=17)

% accurate go

93.8 + 6.2

% accurate stop

BPD (N=26)

t

df

p

85.8 + 11.3

3.0

40.1

.005

54.0 + 11.9

50.9 + 7.7

0.94

25.6

NS

Go reaction time
(msec)
Inhibit delay* (msec)

738.5 + 135.0

733.6 + 87.4

0.13

25.4

NS

508.7 + 138.1

488.0 + 90.8

0.58

39

NS

SSRT** (msec)

229.6 + 52.3

216.3 + 47.4

0.84

38

NS

* Inhibit delay= interval between onset of go and onset of stop signals.
** SSRT= stop signal reaction time. See text for method of calculation.
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Table 3. Significant between-group activations in stop incorrect vs. go contrast in regions
of interest
GROUPS
Region
L/R voxels x
y
z
t
p
accumbens
L
117
-10 14 -2 4.05 .001
C vs. All BPD
caudate
L
395
-10 12 0
4.22 .002
putamen
L
250
-14 16 2
3.74 .008
vPFC
R
312
32 28 -6 3.24 .034
accumbens
R
131
12 14 -8 3.54 .005
caudate
R
468
12 12 0
3.03 .041
putamen
R
270
18 16 -6 3.23 .027
C vs. unmed BPD

accumbens
caudate
putamen
vPFC
accumbens
caudate
putamen

L
L
L
R
R
R
R

127
463
328
190
145
645
285

-10
-10
-14
22
12
18
18

14
12
16
22
14
18
14

-2
0
2
-10
-8
-4
-8

4.09
4.21
4.15
2.96
3.89
3.25
3.66

.001
.002
.003
.061
.002
.001
.010

C vs. med BPD

accumbens
caudate
vPFC
accumbens

L
L
R
R

77
129
355
77

-8
-10
34
10

14
12
26
14

-2
0
-8
-6

2.97
3.06
3.37
2.45

.021
.034
.026
.057

C vs. BPD+ADHD

vPFC
ant cingulate
accumbens
putamen
vPFC
ant cingulate
accumbens
caudate
putamen

L
L
L
L
R
R
R
R
R

232
800
96
343
354
1167
123
562
395

-34
4
-10
-14
34
8
12
12
28

24
40
14
14
32
40
12
12
18

0
12
-2
2
-6
12
-4
0
6

3.24
3.58
3.67
3.60
3.75
3.73
3.29
3.05
3.34

.040
.027
.004
.011
.011
.016
.009
.039
.021

accumbens
L
112
-8 14 0
3.30 .010
caudate
L
206
-8 12 0
3.44 .014
putamen
L
92
-14 16 2
2.83 .062
accumbens
R
114
12 14 -8 2.80 .028
ant cingulate= anterior cingulate; vPFC= ventral prefrontal cortex; C=controls; BPD=patients
with bipolar disorder; med=medicated; unmed=unmedicated; BPD+ADHD=patients with BPD
and ADHD; BPD-ADHD=patients with BPD, without ADHD
Coordinates are in MNI space. Significance is defined as p<.05 on a small volume corrected,
region of interest analysis.
Note: Many areas of activation had multiple significant maxima within the cluster noted. In
the interest of space, only the maximum with the highest t value is reported for each cluster.
C vs. BPD-ADHD
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Table 4. Significant between-group activations in stop correct vs. stop incorrect contrast
in regions of interest
GROUPS
All BPD vs. C

Region
vPFC

L/R
R

voxels
335

x
34

y
26

z
-6

t
3.30

p
.032

Unmed BPD vs. C

accumbens
caudate
putamen
vPFC
ant cingulate
accumbens
caudate
putamen

L
L
L
R
R
R
R
R

65
294
474
417
507
145
551
445

-14
-10
-14
34
10
16
12
26

4
10
10
24
14
16
12
18

-6
8
2
-6
26
-8
20
-6

2.60
3.02
3.13
4.04
3.26
3.03
3.26
3.11

.048
.038
.035
.006
.048
.017
.026
.036

Unmed BPD vs. med BPD

accumbens
putamen
ant cingulate
accumbens
caudate

L
L
R
R
R

36
661
179
108
357

-14
-26
10
10
14

4
10
14
4
12

-12
4
26
-6
22

2.79
3.04
3.46
2.67
3.70

.033
.042
.031
.038
.009

BPD+ADHD vs. C

vPFC
putamen

R
R

412
283

34
30

26
18

-6
4

3.78
3.01

.010
.045

BPD+ADHD vs.
BPD-ADHD

vPFC

L

106

-24 20

-2

3.12

.053

accumbens
L
106
-14 4
-6 3.35 .009
caudate
L
65
-12 16 -2 2.94 .044
putamen
L
740
-16 10 -4 3.61 .011
vPFC
R
362
30 22 -6 3.07 .050
accumbens
R
111
14 12 -12 3.20 .011
putamen
R
790
34 -8 2
4.12 .003
ant cingulate= anterior cingulate; vPFC= ventral prefrontal cortex; C=controls; BPD=patients
with bipolar disorder; med=medicated; unmed=unmedicated; BPD+ADHD=patients with BPD
and ADHD; BPD-ADHD=patients with BPD,without ADHD
Coordinates are in MNI space. Significance is defined as p<.05 on a small volume corrected,
region of interest analysis.
Note: Many areas of activation had multiple significant maxima within the cluster noted. In
the interest of space, only the maximum with the highest t value is reported for each cluster.
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Fig. 1a. Activation on stop incorrect vs. go contrast, controls vs. all bipolar patients. Data
shown at p<.005, whole brain uncorrected, for purposes of presentation. Peak activation in
left caudate, x=-10, y=12, z=0, t=4.22, k E =395, p=.002.

Fig. 1b. Activation at -10, 12, 0 in controls and all bipolar patients on the stop correct vs.
fixation, stop incorrect vs. fixation, and go correct vs. fixation contrasts.
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